Posted by Michael Wonder on 12 Apr 2021
Prevalence of immature survival data for anti-cancer drugs presented to the National Institute for Health and Care Excellence and impact on decision-making
12 April 2021 - This research aims to explore how often NICE uses immature overall survival data to inform reimbursement decisions on cancer treatments, and the implications of this for resource allocation decisions.
NICE cancer technology appraisals published between 2015 and 2017 were reviewed to determine the prevalence of using immature survival data.
A case study was used to demonstrate the potential impact of basing decisions on immature data.
